


**AMENDMENTS TO THE CLAIMS**

Please cancel claims 76, 105-107, 118 and 126-128 and add claims 129-134 as indicated below. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-101 (Canceled).

102. (Original) A compound represented by the formula:



wherein the ring is optionally substituted with one or more R groups, preferably 0, 1 or 2; and wherein:

R<sub>1</sub> is R<sub>5</sub>-(A)<sub>p</sub>-;

R<sub>5</sub> is selected from the group consisting of:

-H,

-Ar<sub>1</sub>,

-CO-Ar<sub>1</sub>,

-SO<sub>2</sub>-Ar<sub>1</sub>,

Appl. No. 09/886,772  
Amdt. Dated December 16, 2003  
Reply to Office Action of June 16, 2003

-R<sub>9</sub>,

-CO-R<sub>9</sub>,

-CO-O-R<sub>9</sub>,

-SO<sub>2</sub>-R<sub>9</sub>,

-CO-N  $\begin{matrix} /Ar_1 \\ \backslash R_{10} \end{matrix}$ ,

-SO<sub>2</sub>-N  $\begin{matrix} /Ar_1 \\ \backslash R_{10} \end{matrix}$ ,

-CO-N  $\begin{matrix} /R_9 \\ \backslash R_{10} \end{matrix}$ , and

-SO<sub>2</sub>-N  $\begin{matrix} /R_9 \\ \backslash R_{10} \end{matrix}$ ;

each A is independently selected from the group  
consisting of any  $\alpha$ -amino acid;

p is 0, 1, 2, 3 or 4;

Y is

-O-,  
-S- or  
-NH; and

R is:

-H,  
-O-C<sub>1-6</sub> alkyl,  
-NH(C<sub>1-6</sub> alkyl),  
-N(C<sub>1-6</sub> alkyl)<sub>2</sub>,  
-S-C<sub>1-6</sub> alkyl,

Appl. No. 09/886,772  
Amdt. Dated December 16, 2003  
Reply to Office Action of June 16, 2003

-C<sub>1-6</sub> alkyl, or  
-Q<sub>2</sub>;

each R<sub>9</sub> is a C<sub>1-6</sub> straight or branched alkyl group optionally singly or multiply substituted by -OH, -F, or =O and optionally substituted with one Ar<sub>1</sub> group;

each R<sub>10</sub> is independently selected from the group consisting of -H or a C<sub>1-6</sub> straight or branched alkyl group;

each T<sub>1</sub> is independently selected from the group consisting of:

-CH=CH-,  
-O-,  
-S-,  
-SO-,  
-SO<sub>2</sub>-,  
-NR<sub>10</sub>-,  
-NR<sub>10</sub>-CO-,  
-CO-,  
-O-CO-,  
-CO-O-,  
-CO-NR<sub>10</sub>-,  
-O-CO-NR<sub>10</sub>-,  
-NR<sub>10</sub>-CO-O-,  
-NR<sub>10</sub>-CO-NR<sub>10</sub>-,  
-SO<sub>2</sub>-NR<sub>10</sub>-,  
-NR<sub>10</sub>-SO<sub>2</sub>-, and  
-NR<sub>10</sub>-SO<sub>2</sub>-NR<sub>10</sub>-,

each Ar<sub>1</sub> is a cyclic group independently selected from the set consisting of an aryl group which contains 6, 10, 12, or

14 carbon atoms and between 1 and 3 rings, a cycloalkyl group which contains between 3 and 15 carbon atoms and between 1 and 3 rings, said cycloalkyl group being optionally benzofused, and a heterocycle group containing between 5 and 15 ring atoms and between 1 and 3 rings, said heterocycle group containing at least one heteroatom group selected from -O-, -S-, -SO-, -SO<sub>2</sub>-, =N-, and -NH-, said heterocycle group optionally containing one or more double bonds, said heterocycle group optionally comprising one or more aromatic rings, and said cyclic group optionally being singly or multiply substituted by -NH<sub>2</sub>, -CO<sub>2</sub>H, -Cl, -F, -Br, -I, -NO<sub>2</sub>, -CN, =O, -OH, -perfluoro C<sub>1-3</sub> alkyl,  $\begin{array}{c} \text{O} \\ / \quad \backslash \\ \quad \text{CH}_2, \\ \backslash \quad / \\ \text{O} \end{array}$  or -Q<sub>1</sub>;


each Q<sub>1</sub> is independently selected from the group consisting of:

-Ar<sub>1</sub>  
-R<sub>9</sub>,  
-T<sub>1</sub>-R<sub>9</sub>,                      and  
-(CH<sub>2</sub>)<sub>1,2,3</sub>-T<sub>1</sub>-R<sub>9</sub>;


each Q<sub>2</sub> is independently selected from the group consisting of -OH, -NH<sub>2</sub>, -CO<sub>2</sub>H, -Cl, -F, -Br, -I, -NO<sub>2</sub>, -CN, -CF<sub>3</sub>, and  $\begin{array}{c} \text{O} \\ / \quad \backslash \\ \quad \text{CH}_2; \\ \backslash \quad / \\ \text{O} \end{array}$

provided that when -Ar<sub>1</sub> is substituted with a Q<sub>1</sub> group which comprises one or more additional -Ar<sub>1</sub> groups, said additional -Ar<sub>1</sub> groups are not substituted with Q<sub>1</sub>.

103. (Original) A compound according to claim 102  
selected from the group consisting of:



Appl. No. 09/886,772  
Amdt. Dated December 16, 2003  
Reply to Office Action of June 16, 2003



104. (Original) A compound according to claim 102 wherein each A is independently selected from the group consisting of the  $\alpha$ -amino acids:

alanine,  
histidine,  
lysine,  
phenylalanine,  
proline,  
tyrosine,  
valine,  
leucine,  
isoleucine,  
glutamine,  
methionine,  
homoproline,  
3-(2-thienyl) alanine, and  
3-(3-thienyl) alanine.

105-124 (Canceled).

125. (Previously presented) A composition comprising a compound according to any one of claims 102-104 and a carrier.

126-128 (Canceled).

129. (New) The method for inhibiting IL-1 $\beta$  secretion by LPS-stimulated human adherent mononuclear cells comprising administering to a mammal in need thereof a compound according to any one of claims 102-104 for a time and under conditions effective to inhibit interleukin-1 $\beta$  converting enzyme.

130. (New) A method for inhibiting IL-1 $\beta$  secretion by LPS-stimulated human peripheral blood monocytes comprising administering to a mammal in need thereof a compound according to any one of claims 102-104 for a time and under conditions effective to inhibit interleukin-1 $\beta$  converting enzyme.

131. (New) A method of inhibiting interleukin-1 $\beta$  converting enzyme comprising administering to a mammal in need thereof a compound according to any one of claims 102-104 for a time and under conditions effective to inhibit interleukin-1 $\beta$  converting enzyme.

132. (New) The method according to claim 131, wherein the mammal is afflicted with a disease selected from the group consisting of septic shock, septicemia, adult respiratory distress syndrome, rheumatoid arthritis, systemic

Appl. No. 09/886,772  
Amdt. Dated December 16, 2003  
Reply to Office Action of June 16, 2003

lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and primary lateral sclerosis.

133. (New) The method according to claim 131, wherein the mammal is afflicted with an infectious disease.

134. (New) A method of inhibiting interleukin-1 $\beta$  converting enzyme comprising administering to a mammal in need of wound healing, a compound according to any one of claims 102-104 for a time and under conditions effective to inhibit interleukin-1 $\beta$  converting enzyme.